A comprehensive analysis of germline predisposition to early-onset ovarian cancer

The subset of ovarian cancer (OC) diagnosed ≤ 30yo represents a distinct subgroup exhibiting disparities from late-onset OC in many aspects, including indefinite germline cancer predisposition. We performed DNA/RNA-WES with HLA-typing, PRS assessment and survival analysis in 123 early-onset OC-patients compared to histology/stage-matched late-onset and unselected OC-patients, and population-matched controls. Only 6/123(4.9%) early-onset OC-patients carried a germline pathogenic variant (GPV) in high-penetrance OC-predisposition genes. Nevertheless, our comprehensive germline analysis of early-onset OC-patients revealed two divergent trajectories of potential germline susceptibility. Firstly, overrepresentation analysis highlighted a connection to breast cancer (BC) that was supported by the CHEK2 GPV enrichment in early-onset OC( p = 1.2 × 10 –4 ), and the presumably BC-specific PRS 313 , which successfully stratified early-onset OC-patients from controls( p = 0.03). The second avenue pointed towards the impaired immune response, indicated by LY75-CD302 GPV( p = 8.3 × 10 –4 ) and diminished HLA diversity compared with controls( p = 3 × 10 –7 ). Furthermore, we found a significantly higher overall GPV burden in early-onset OC-patients compared to controls( p = 3.8 × 10 –4 ). The genetic predisposition to early-onset OC appears to be a heterogeneous and complex process that goes beyond the traditional Mendelian monogenic understanding of hereditary cancer predisposition, with a significant role of the immune system. We speculate that rather a cumulative overall GPV burden than specific GPV may potentially increase OC risk, concomitantly with reduced HLA diversity.